{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:06:34Z","timestamp":1789679194240,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bulcan.2026.07.012","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:55:05Z","timestamp":1789678505000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumeurs t\u00e9nosynoviales \u00e0 cellules g\u00e9antes (TGCT)\u00a0: de la physiopathologie \u00e0 l\u2019\u00e9mergence de nouvelles th\u00e9rapies cibl\u00e9es"],"prefix":"10.1016","author":[{"given":"Nelly","family":"Firmin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ryckewaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Amouyel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Tetreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Llacer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vinches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Delfour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0340","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0025-7125(16)33356-9","article-title":"Pigmented villonodular synovitis","volume":"49","author":"Larmon","year":"1965","journal-title":"Med Clin North Am"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.012_bib0345","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1\u00a0expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.012_bib0350","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00005792-198005000-00004","article-title":"Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166\u00a0cases and literature review","volume":"59","author":"Myers","year":"1980","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.012_bib0355","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors: a nationwide study in The Netherlands","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop"},{"issue":"2","key":"10.1016\/j.bulcan.2026.07.012_bib0360","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","article-title":"Tenosynovial giant cell tumour\/pigmented villonodular synovitis: Outcome of 294\u00a0patients before the era of kinase inhibitors","volume":"51","author":"Palmerini","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.012_bib0365","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.semarthrit.2010.07.005","article-title":"Pigmented villonodular synovitis: a retrospective single-center study of 122\u00a0cases and review of the literature","volume":"40","author":"Ottaviani","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.bulcan.2026.07.012_bib0370","doi-asserted-by":"crossref","first-page":"107953","DOI":"10.1016\/j.ejso.2024.107953","article-title":"Active surveillance of diffuse-type tenosynovial giant cell tumors: a retrospective, multicenter cohort study","volume":"50","author":"Spierenburg","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.07.012_bib0375","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/jso.27067","article-title":"A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: a 2-year observational analysis","volume":"126","author":"Bernthal","year":"2022","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.07.012_bib0380","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41379-018-0129-0","article-title":"Malignant tenosynovial giant cell tumor: the true \u201csynovial sarcoma?\u201d a clinicopathologic, immunohistochemical, and molecular cytogenetic study of 10\u00a0cases, supporting origin from synoviocytes","volume":"32","author":"Al-Ibraheemi","year":"2019","journal-title":"Modern Pathol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.07.012_bib0385","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/PAS.0b013e3181a6d86f","article-title":"Clusterin is expressed in normal synoviocytes and in tenosynovial giant cell tumors of localized and diffuse types: diagnostic and histogenetic implications","volume":"33","author":"Boland","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.012_bib0390","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","article-title":"Translocation and expression of CSF1\u00a0in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides","volume":"31","author":"Cupp","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0395","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fimmu.2019.02019","article-title":"Function of CSF1\u00a0and IL34\u00a0in macrophage homeostasis, inflammation, and cancer","volume":"10","author":"Lin","year":"2019","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.bulcan.2026.07.012_bib0400","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1158\/1078-0432.CCR-22-1898","article-title":"Interactions in CSF1-driven tenosynovial giant cell tumors","volume":"28","author":"van IJzendoorn","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.012_bib0405","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/futurepharmacol3040056","article-title":"Overview of pharmacological therapies for diffuse tenosynovial giant cell tumor","volume":"3","author":"Stamatiou","year":"2023","journal-title":"Future Pharmacol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.07.012_bib0410","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/medicina58091270","article-title":"PD-L1\u00a0status in tenosynovial giant cell tumors","volume":"58","author":"Zenginkinet","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.012_bib0415","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00243061","article-title":"Giant cell tumor of tendon sheath: spectrum of radiologic findings","volume":"21","author":"Karasick","year":"1992","journal-title":"Skeletal Radiol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.012_bib0420","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.3892\/ol.2017.6011","article-title":"Giant cell tumor of the tendon sheath: magnetic resonance imaging findings in 38\u00a0patients","volume":"13","author":"Wang","year":"2017","journal-title":"Oncol Lett"},{"issue":"5","key":"10.1016\/j.bulcan.2026.07.012_bib0425","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1148\/rg.285085134","article-title":"Pigmented villonodular synovitis: radiologic-pathologic correlation","volume":"28","author":"Murphey","year":"2008","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0430","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2214\/ajr.172.1.9888766","article-title":"Pigmented villonodular synovitis and related lesions: the spectrum of imaging findings","volume":"172","author":"Lin","year":"1999","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0435","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.suronc.2020.08.030","article-title":"The effect of imatinib mesylate in diffuse-type tenosynovial giant cell tumours on MR imaging and PET-CT","volume":"35","author":"Mastboom","year":"2020","journal-title":"Surg Oncol"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0440","doi-asserted-by":"crossref","first-page":"115368","DOI":"10.1016\/j.ejca.2025.115368","article-title":"Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspects","volume":"220","author":"Hofer","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0445","doi-asserted-by":"crossref","first-page":"102491","DOI":"10.1016\/j.ctrv.2022.102491","article-title":"Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts","volume":"112","author":"Stacchiotti","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.012_bib0450","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.21873\/anticanres.17496","article-title":"Mismatch between preoperative MRI findings and postoperative histological results in the treatment of tenosynovial giant cell tumor","volume":"45","author":"Neugebauer","year":"2025","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.012_bib0455","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","article-title":"Patient-reported symptoms of tenosynovial giant cell tumors","volume":"38","author":"Gelhorn","year":"2016","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0460","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2196\/ijmr.9325","article-title":"The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life","volume":"7","author":"Mastboom","year":"2018","journal-title":"Interact J Med Res"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0465","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/2156-7514.152343","article-title":"Malignant tenosynovial giant cell tumor of the leg: a radiologic-pathologic correlation and review of the literature","volume":"5","author":"Richman","year":"2015","journal-title":"J Clin Imaging Sci"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0470","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13569-015-0030-2","article-title":"Metastasizing tenosynovial giant cell tumour, diffuse type\/pigmented villonodular synovitis","volume":"5","author":"Righi","year":"2015","journal-title":"Clin Sarcoma Res"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0475","first-page":"63","article-title":"Malignant diffuse tenosynovial giant cell tumor: case report and review of the literature","volume":"26","author":"MacMahon","year":"2021","journal-title":"AJSP Rev Rep"},{"issue":"2","key":"10.1016\/j.bulcan.2026.07.012_bib0480","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41379-018-0129-0","article-title":"Malignant tenosynovial giant cell tumor: the true \u201csynovial sarcoma?\u201d A clinicopathologic, immunohistochemical, and molecular cytogenetic study of 10\u00a0cases, supporting origin from synoviocytes","volume":"32","author":"Al-Ibraheemi","year":"2019","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0485","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1186\/s12885-018-5188-6","article-title":"Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy","volume":"18","author":"Nakayama","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0490","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CAD.0000000000000844","article-title":"Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour","volume":"31","author":"Rebuzzi","year":"2020","journal-title":"Anticancer Drugs"},{"issue":"12","key":"10.1016\/j.bulcan.2026.07.012_bib0495","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/14796694.2025.2488635","article-title":"Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry","volume":"21","author":"Stern","year":"2025","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.012_bib0500","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","article-title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study","volume":"20","author":"Mastboom","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0505","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13023-021-01883-5","article-title":"Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry","volume":"16","author":"Lopez-Bastida","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"10197","key":"10.1016\/j.bulcan.2026.07.012_bib0510","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3\u00a0trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.012_bib0515","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1093\/oncolo\/oyad011","article-title":"Tenosynovial giant cell tumor observational platform project (TOPP) registry: a 2-year analysis of patient-reported outcomes and treatment strategies","volume":"28","author":"Palmerini","year":"2023","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.012_bib0520","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jso.23220","article-title":"A multidisciplinary approach to giant cell tumors of tendon sheath and synovium\u00a0\u2013\u00a0a critical appraisal of literature and treatment proposal","volume":"107","author":"Van Der Heijden","year":"2013","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.012_bib0525","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.knee.2017.03.011","article-title":"Pigmented villonodular synovitis of the knee: a retrospective analysis of 214\u00a0cases at a UK tertiary referral centre","volume":"24","author":"Patel","year":"2017","journal-title":"Knee"},{"issue":"28","key":"10.1016\/j.bulcan.2026.07.012_bib0530","doi-asserted-by":"crossref","first-page":"e26659","DOI":"10.1097\/MD.0000000000026659","article-title":"Image-guided, intensity-modulated radiotherapy for the treatment of diffuse-type tenosynovial giant cell tumor of the knee: case report and review of the literature","volume":"100","author":"Xiang","year":"2021","journal-title":"Medicine"},{"issue":"19","key":"10.1016\/j.bulcan.2026.07.012_bib0535","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1002\/cncr.26529","article-title":"Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor\/pigmented villonodular synovitis with radiotherapy and surgery","volume":"118","author":"Griffin","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.012_bib0540","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.prro.2022.11.004","article-title":"Long-term outcomes of diffuse or recurrent tenosynovial giant cell tumor treated with postoperative external beam radiation therapy","volume":"13","author":"Baniel","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0545","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijrobp.2009.07.1747","article-title":"Radiation therapy for treatment of pigmented villonodular synovitis: results of a national patterns of care study","volume":"78","author":"Heyd","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5\u20136","key":"10.1016\/j.bulcan.2026.07.012_bib0550","first-page":"320","article-title":"Les synoviorth\u00e8ses radio-isotopiques\u00a0: synth\u00e8se des indications et des diff\u00e9rents r\u00e9sultats rapport\u00e9s dans la litt\u00e9rature","volume":"44","author":"Isenborghs","year":"2020","journal-title":"Med Nucl"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0555","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.69520","article-title":"The use of radiosynovectomy using Yttrium-90\u00a0as an adjunct to mechanical synovectomy for pigmented villonodular synovitis: how effective is this?","author":"Al-Janabi","year":"2024","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.bulcan.2026.07.012_bib0560","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1302\/0301-620X.100B7.BJJ-2017-0867.R3","article-title":"Inconclusive benefit of adjuvant 90Yttrium hydroxyapatite to radiosynovectomy for diffuse-type tenosynovial giant-cell tumour of the knee","volume":"100-B","author":"Gortzak","year":"2018","journal-title":"Bone Joint J"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0565","doi-asserted-by":"crossref","first-page":"14551","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.012_bib0570","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.26409","article-title":"Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis","volume":"118","author":"Cassier","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0575","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2045-3329-3-8","article-title":"Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib","volume":"3","author":"Stacchiotti","year":"2013","journal-title":"Clin Sarcoma Res"},{"issue":"5","key":"10.1016\/j.bulcan.2026.07.012_bib0580","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2\u00a0trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0585","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2022.06.028","article-title":"Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT","volume":"173","author":"Spierenburg","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10197","key":"10.1016\/j.bulcan.2026.07.012_bib0590","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3\u00a0trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.012_bib0595","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.33312","article-title":"Long-term outcomes of pexidartinib in tenosynovial giant cell tumors","volume":"127","author":"Gelderblom","year":"2021","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bulcan.2026.07.012_bib0600","doi-asserted-by":"crossref","first-page":"oyae345","DOI":"10.1093\/oncolo\/oyae345","article-title":"Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study","volume":"30","author":"Wagner","year":"2025","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0605","doi-asserted-by":"crossref","first-page":"e35634","DOI":"10.1002\/cncr.35634","article-title":"A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib","volume":"131","author":"Desai","year":"2025","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2026.07.012_bib0610","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1158\/1535-7163.MCT-21-0361","article-title":"Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages","volume":"20","author":"Smith","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"10.1016\/j.bulcan.2026.07.012_bib0615","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-24-0103","article-title":"CSF1R inhibition in patients with advanced solid tumors or tenosynovial giant cell tumor: a phase I study of vimseltinib","volume":"30","author":"Gelderblom","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10445","key":"10.1016\/j.bulcan.2026.07.012_bib0620","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","article-title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"403","author":"Gelderblom","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.012_bib0625","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ajpath.2011.03.029","article-title":"Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury","volume":"179","author":"Radi","year":"2011","journal-title":"Am J Pathol"},{"issue":"16_suppl","key":"10.1016\/j.bulcan.2026.07.012_bib0630","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1200\/JCO.2023.41.16_suppl.11559","article-title":"Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): phase 1b update","volume":"41","author":"Yao","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0635","first-page":"1","article-title":"MANEUVER: a phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients","author":"Niu","year":"2024","journal-title":"Future Oncol"},{"issue":"10533","key":"10.1016\/j.bulcan.2026.07.012_bib0640","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0140-6736(25)02602-9","article-title":"Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3\u00a0trial","volume":"407","author":"Xu","year":"2026","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bulcan.2026.07.012_bib0645","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","article-title":"CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1\u00a0study","volume":"16","author":"Cassier","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0650","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","article-title":"Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour","volume":"141","author":"Cassier","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0655","series-title":"A phase III, multicentre, randomised, double-blind study to assess the safety and efficacy of emactuzumab vs. placebo in subjects with tenosynovial giant cell tumour [Clinical trial registration] [Internet]","year":"2026"},{"key":"10.1016\/j.bulcan.2026.07.012_bib0660","doi-asserted-by":"crossref","first-page":"S1226","DOI":"10.1016\/j.annonc.2022.07.1589","article-title":"1486MO The synovial and systemic pharmacokinetics and pharmacodynamics of intra-articular administration of the CSF1\u00a0receptor antibody AMB-05X in a phase II proof-of-concept trial in tenosynovial giant cell tumor","volume":"33","author":"Gelderblom","year":"2022","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.bulcan.2026.07.012_bib0665","doi-asserted-by":"crossref","first-page":"TPS11585","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS11585","article-title":"A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor","volume":"41","author":"Gelderblom","year":"2023","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2026.07.012_bib0335","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:55:12Z","timestamp":1789678512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":67,"alternative-id":["S0007455126003954"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.012","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumeurs t\u00e9nosynoviales \u00e0 cellules g\u00e9antes (TGCT)\u00a0: de la physiopathologie \u00e0 l\u2019\u00e9mergence de nouvelles th\u00e9rapies cibl\u00e9es","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}